Is Boston Therapeutics, Inc. (BTHE) a Buy, Sell, or Hold?
OTC : BTHE
Boston Therapeutics, Inc.
$0.01 USD
$0 (0.0%)
- Volume
- 105.24K
- Average Volume
- 169.8K
- Market Capitalization
- $0
- P/E Ratio
- -1.22
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.07
- Year Low
- $0.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.00
Company Overview
OTC
Chi-Heng Cheng
Biotechnology
Healthcare
BTHE
N/A
US
USD
Liquidity Metrics
-0.56
0.00
0.00
0.00
0.00
Sales & Valuation
$9336
0.00
-0.13
0.00
-0.01
Profitability
-$0.0082
-$907.88K
-9724.54%
-9724.54%
11.17%
-4562.23%
P/E Metrics
-1.22
0.00
0.00
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
No financial score data available.
Key Metrics (TTM)
$4.83M
517.14
-10.11
0.00
11.17%
20.99%
-81.69%
%
-6023 days
Company Executives
No executive data available.
Poll Results
No votes yet today — be the first to share your view!
About Boston Therapeutics, Inc. (OTC:BTHE) Stock
Founded in 2009 and headquartered in Lawrence, Massachusetts, Boston Therapeutics, Inc. operates as a pre-clinical and clinical-stage pharmaceutical development firm. The company specializes in the development, manufacturing, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements within the United States. Its pipeline features several key drug candidates: BTI-320, a non-systemic carbohydrate compound currently in Phase IIb clinical trials, engineered to mitigate post-meal increases in blood glucose levels for patients with Type 2 diabetes and pre-diabetes; BTI-410, an injectable peptide compound that has completed Phase Ib clinical trials, developed for Type 1 immunosuppression therapy post-kidney transplant and for Type 2 diabetes patients; and IPOXYN, an in ... jectable carbohydrate drug designed to prevent necrosis (cell death) and alleviate hypoxic conditions such as diabetic foot ulcers and other vascular/neurological complications. Furthermore, Boston Therapeutics markets SUGARDOWN, a non-systemic complex carbohydrate dietary supplement supporting healthy post-meal blood glucose levels. The company previously operated as Avanyx Therapeutics, Inc. before adopting its current name in November 2010.
Frequently Asked Questions
-
What is the current Boston Therapeutics, Inc. (BTHE) stock price?
-
Boston Therapeutics, Inc.(OTC:BTHE) stock price is $0.01 in the last trading session. During the trading session, BTHE stock reached the peak price of $0.0119 while $0.0091 was the lowest point it dropped to. The percentage change in BTHE stock occurred in the recent session was 0.0% while the dollar amount for the price change in BTHE stock was $0.
-
BTHE's industry and sector of operation?
-
The OTC listed BTHE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BTHE?
-
|
|
|
|
| -
How many employees does BTHE have?
-
Number of BTHE employees currently stands at None. BTHE operates from 354 Merrimack Street #4, Lawrence, MA 01843, US.
-
Link for BTHE official website?
-
Official Website of BTHE is: http://www.bostonti.com
-
How do I contact BTHE?
-
BTHE could be contacted at phone #603 935 9799 and can also be accessed through its website. BTHE operates from 354 Merrimack Street #4, Lawrence, MA 01843, US.
-
How many shares of BTHE are traded daily?
-
The average number of BTHE shares traded daily for last 3 months was 169.8K.
-
What is the market cap of BTHE currently?
-
The market value of BTHE currently stands at $0 with its latest stock price at $0.01